Dynavax Technologies Gelecekteki Büyüme

Future kriter kontrolleri 4/6

Dynavax Technologies kazanç ve gelirinin sırasıyla yıllık 33.4% ve 16.5% oranında artması tahmin edilirken, EPS'nin yıllık 31.4% oranında büyümesi bekleniyor.

Anahtar bilgiler

33.4%

Kazanç büyüme oranı

31.4%

EPS büyüme oranı

Biotechs kazanç büyümesi	27.2%
Gelir büyüme oranı	16.5%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	21 Jan 2025

Gelecekteki son büyüme güncellemeleri

Recent updates

Dynavax Technologies: What The Stock Buyback Means, What It Doesn't

Nov 13

Dynavax Technologies Corporation (NASDAQ:DVAX) Surges 31% Yet Its Low P/S Is No Reason For Excitement

Nov 12

Lacklustre Performance Is Driving Dynavax Technologies Corporation's (NASDAQ:DVAX) Low P/S

May 22

Dynavax: HEPLISAV-B Growth Up, Pipeline Uncertain

May 10

Dynavax: Holding Firm Despite Its Missing Cash Cow

Mar 23

Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?

Mar 06

Dynavax Technologies Corporation's (NASDAQ:DVAX) Business And Shares Still Trailing The Industry

Jan 31

These 4 Measures Indicate That Dynavax Technologies (NASDAQ:DVAX) Is Using Debt Safely

Aug 02

Improved Earnings Required Before Dynavax Technologies Corporation (NASDAQ:DVAX) Shares Find Their Feet

Jun 02

We Think Dynavax Technologies (NASDAQ:DVAX) Can Manage Its Debt With Ease

May 03

Dynavax Technologies (NASDAQ:DVAX) Seems To Use Debt Rather Sparingly

Jan 16

Clover, Dynavax COVID-19 vaccine gets EU GMP certificate

Sep 20

Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?

Sep 12

The Alphavaxers: Dynavax And Novavax, 2 Quarters On

Aug 22

Dynavax up 8% after raising full-year guidance for key adjuvant product, Q2 beats

Aug 04

Are Investors Undervaluing Dynavax Technologies Corporation (NASDAQ:DVAX) By 41%?

Jun 03

Dynavax: Evolving Endemic Situation Adds To Its Risk

May 23

Dynavax Technologies' (NASDAQ:DVAX) Performance Is Even Better Than Its Earnings Suggest

May 12

Dynavax Technologies (NASDAQ:DVAX) Could Easily Take On More Debt

May 10

Dynavax Technologies: Full Speed Ahead

Mar 01

Here's Why Dynavax Technologies (NASDAQ:DVAX) Can Manage Its Debt Responsibly

Jan 28

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGS:DVAX - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2027	464	102	111	N/A	3
12/31/2026	386	70	69	96	4
12/31/2025	334	50	40	72	5
12/31/2024	278	27	7	18	5
9/30/2024	261	20	23	27	N/A
6/30/2024	250	17	35	39	N/A
3/31/2024	236	9	53	56	N/A
12/31/2023	232	-6	96	101	N/A
9/30/2023	361	61	118	122	N/A
6/30/2023	459	111	147	152	N/A
3/31/2023	656	236	134	141	N/A
12/31/2022	723	293	56	63	N/A
9/30/2022	733	320	140	148	N/A
6/30/2022	674	228	142	153	N/A
3/31/2022	470	104	238	247	N/A
12/31/2021	439	72	326	336	N/A
9/30/2021	258	-39	192	199	N/A
6/30/2021	163	-6	101	105	N/A
3/31/2021	113	-62	-31	-27	N/A
12/31/2020	40	-75	-103	-92	N/A
9/30/2020	38	-97	-112	-100	N/A
6/30/2020	35	-138	-115	-94	N/A
3/31/2020	40	-129	-136	-108	N/A
12/31/2019	35	-156	-151	-121	N/A
9/30/2019	30	-159	-161	-132	N/A
6/30/2019	21	-163	-166	-144	N/A
3/31/2019	14	-160	-157	-141	N/A
12/31/2018	8	-159	-146	-131	N/A
9/30/2018	3	-146	-130	-115	N/A
6/30/2018	1	-128	N/A	-99	N/A
3/31/2018	0	-109	N/A	-82	N/A
12/31/2017	0	-95	N/A	-78	N/A
9/30/2017	8	-89	N/A	-86	N/A
6/30/2017	8	-102	N/A	-97	N/A
3/31/2017	10	-111	N/A	-105	N/A
12/31/2016	11	-112	N/A	-107	N/A
9/30/2016	4	-118	N/A	-103	N/A
6/30/2016	5	-113	N/A	-97	N/A
3/31/2016	4	-108	N/A	-96	N/A
12/31/2015	4	-107	N/A	-93	N/A
9/30/2015	6	-102	N/A	-88	N/A
6/30/2015	7	-102	N/A	-88	N/A
3/31/2015	8	-103	N/A	-87	N/A
12/31/2014	11	-91	N/A	-74	N/A
9/30/2014	12	-90	N/A	-69	N/A
6/30/2014	12	-76	N/A	-58	N/A
3/31/2014	13	-68	N/A	-51	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: DVAX 'nin tahmini kazanç büyümesi (yıllık 33.4% ) tasarruf oranının ( 2.6% ) üzerindedir.

Kazançlar ve Piyasa: DVAX şirketinin kazançlarının (yıllık 33.4% ) US pazarından (yıllık 14.9% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: DVAX şirketinin kazançlarının önümüzdeki 3 yıl içerisinde önemli ölçüde artması bekleniyor.

Gelir ve Pazar: DVAX şirketinin gelirinin (yıllık 16.5% ) US pazarından (yıllık 9% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: DVAX şirketinin gelirinin (yıllık 16.5% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: DVAX 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Büyüyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/01/22 23:54
Gün Sonu Hisse Fiyatı	2025/01/22 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Dynavax Technologies Corporation 15 Bu analistlerden 5, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Elemer Piros	Cantor Fitzgerald & Co.
Joshua Schimmer	Evercore ISI
Jonathan Miller	Evercore ISI

Dynavax Technologies Gelecekteki Büyüme

Future kriter kontrolleri 4/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Consensus EPS estimates increase by 23%, revenue downgraded

Dynavax Technologies Corporation Reaffirms Financial Guidance for the Full Year 2024

Dynavax Technologies Corporation Provides Revenue Guidance for the Year 2024

Consensus EPS estimates fall by 39%

Consensus estimates of losses per share improve by 49%

Dynavax Technologies Corporation Revises Earnings Guidance for the Full Year 2023

Recent updates

Dynavax Technologies: What The Stock Buyback Means, What It Doesn't

Dynavax Technologies Corporation (NASDAQ:DVAX) Surges 31% Yet Its Low P/S Is No Reason For Excitement

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Dynavax Technologies Corporation (NasdaqGS:DVAX) announces an Equity Buyback for $200 million worth of its shares.

Dynavax Technologies Corporation to Report Q3, 2024 Results on Nov 07, 2024

Is Dynavax Technologies (NASDAQ:DVAX) Using Debt In A Risky Way?

Dynavax Technologies: Slow And Steady Wins The Race

Dynavax Technologies: A Two Trick Pony Operating With A Single Trick

Some May Be Optimistic About Dynavax Technologies' (NASDAQ:DVAX) Earnings

Consensus EPS estimates increase by 23%, revenue downgraded

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Dynavax Technologies Corporation to Report Q2, 2024 Results on Aug 06, 2024

Is Dynavax Technologies (NASDAQ:DVAX) Weighed On By Its Debt Load?

Dynavax Technologies Corporation Initiates Phase 1/2 Study of Novel Shingles Vaccine Program

Lacklustre Performance Is Driving Dynavax Technologies Corporation's (NASDAQ:DVAX) Low P/S

Dynavax Technologies Corporation Provides Regulatory Update on sBLA for Four-Dose HEPLISAV-B® Regimen for Adults on Hemodialysis in the U.S

Dynavax: HEPLISAV-B Growth Up, Pipeline Uncertain

Dynavax Technologies Corporation Reaffirms Financial Guidance for the Full Year 2024

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Dynavax Technologies Corporation to Report Q1, 2024 Results on May 08, 2024

Dynavax Technologies Corporation, Annual General Meeting, May 23, 2024

Dynavax: Holding Firm Despite Its Missing Cash Cow

Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?

New minor risk - Shareholder dilution

Full year 2023 earnings: EPS exceeds analyst expectations

Dynavax Technologies Corporation Provides Revenue Guidance for the Year 2024

Dynavax Technologies Corporation to Report Q4, 2023 Results on Feb 22, 2024

CEO & Director exercised options and sold US$219k worth of stock

Dynavax Technologies Corporation's (NASDAQ:DVAX) Business And Shares Still Trailing The Industry

Consensus EPS estimates fall by 39%

Insider notifies of intention to sell stock

President & COO notifies of intention to sell stock

Consensus estimates of losses per share improve by 49%

President & COO notifies of intention to sell stock

Dynavax Technologies Corporation Revises Earnings Guidance for the Full Year 2023

Dynavax Technologies Corporation to Report Q3, 2023 Results on Nov 02, 2023

President & COO notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Insider notifies of intention to sell stock

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

These 4 Measures Indicate That Dynavax Technologies (NASDAQ:DVAX) Is Using Debt Safely

Dynavax Technologies Corporation to Report Q2, 2023 Results on Aug 03, 2023

Improved Earnings Required Before Dynavax Technologies Corporation (NASDAQ:DVAX) Shares Find Their Feet

President & COO recently sold US$191k worth of stock

Dynavax Technologies Corporation Reaffirms Revenue Guidance for the Year 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

We Think Dynavax Technologies (NASDAQ:DVAX) Can Manage Its Debt With Ease

CEO & Director exercised options and sold US$311k worth of stock

Consensus revenue estimates fall by 39%

Full year 2022 earnings: EPS exceeds analyst expectations

Dynavax Technologies Corporation to Report Q4, 2022 Results on Feb 23, 2023

Dynavax Technologies (NASDAQ:DVAX) Seems To Use Debt Rather Sparingly

Price target decreased to US$22.75

President & COO recently sold US$651k worth of stock

President & COO recently sold US$651k worth of stock

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: US$0.50 (vs US$0.24 loss in 3Q 2021)

Dynavax Technologies Corporation Provides Revenue Guidance for the Year 2022

Dynavax Technologies Corporation to Report Q3, 2022 Results on Nov 03, 2022

Clover, Dynavax COVID-19 vaccine gets EU GMP certificate

Dynavax Technologies Corporation Announces First Participant Dosed in A Phase 2 Clinical Trial Evaluating an Adjuvanted Plague Vaccine

Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?

The Alphavaxers: Dynavax And Novavax, 2 Quarters On

Investor sentiment deteriorated over the past week

Consensus EPS estimates increase by 51%

Insider exercised options and sold US$178k worth of stock

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Dynavax Technologies Corporation Revises Earnings Guidance for the Year 2022

Dynavax up 8% after raising full-year guidance for key adjuvant product, Q2 beats